Amundi Buys 9,338 Shares of Natera, Inc. $NTRA

Amundi raised its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 315,654 shares of the medical research company's stock after purchasing an additional 9,338 shares during the quarter. Amundi owned 0.22% of Natera worth $85,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of NTRA. Trust Co. of Vermont bought a new position in Natera in the second quarter valued at $26,000. Reflection Asset Management bought a new stake in Natera during the fourth quarter worth about $29,000. Elevation Wealth Partners LLC purchased a new position in shares of Natera in the 2nd quarter worth about $30,000. Palladiem LLC purchased a new position in shares of Natera in the 4th quarter worth about $31,000. Finally, Horizon Investments LLC bought a new position in shares of Natera during the 3rd quarter valued at about $32,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Chapman sold 3,580 shares of the company's stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the completion of the sale, the chief executive officer directly owned 102,973 shares in the company, valued at approximately $26,162,350.11. The trade was a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 71,206 shares of company stock worth $19,944,069. 5.05% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTRA. Leerink Partners set a $330.00 price objective on Natera in a report on Friday, August 7th. TD Cowen upped their target price on Natera from $325.00 to $340.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. UBS Group increased their price target on shares of Natera from $290.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on shares of Natera in a research report on Friday, June 5th. They issued a "neutral" rating and a $245.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $330.83.

Natera Stock Performance

Shares of NTRA stock opened at $330.31 on Thursday. The business's 50 day moving average price is $295.87 and its 200-day moving average price is $240.25. The firm has a market cap of $47.61 billion, a P/E ratio of -242.87 and a beta of 1.54. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $343.18.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's revenue for the quarter was up 37.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) EPS. As a group, equities analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.